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Brief Definit ive Report
The splenic marginal zone (MZ) is located at 
the border of the white pulp and red pulp. The 
arterial circulation of the spleen terminates in a 
porous vascular sinus, the marginal sinus, which 
lies in the MZ. Blood from the marginal sinus 
then transits through the MZ and into the red 
pulp (Mebius and Kraal, 2005). The MZ con-
tains specialized macrophages, B cells, and den-
dritic cells. Cells in the MZ are continuously 
exposed to antigens carried in the blood 
(Mebius and Kraal, 2005).
MZ B cells differ from follicular B cells in 
several ways. Murine MZ B cells do not recir-
culate; they have a partially activated phenotype 
that allows for quick and vigorous antibody re-
sponses to blood-borne antigens and they are 
able to self-renew (Martin and Kearney, 2002). 
Additionally, MZ B cells differ from follicular 
B cells immunophenotypically by high surface 
expression of IgM, the complement receptor 
CD21, and the nonclassical major histocompat-
ibility complex I molecule CD1d that allows 
for presentation of lipid antigens (Pillai and 
Cariappa, 2009). In vitro experiments have shown 
that MZ B cells can present CD1d-restricted 
lipid antigens to invariant (i) NKT cells, although 
their in vivo contribution to CD1d-restricted 
antibody responses has not been determined 
(Barral et al., 2008; Leadbetter et al., 2008).
It is thought that positioning of MZ B cells 
is dependent on signaling through various 
G protein–coupled receptors specifically through 
receptors coupled to Gi, as treatment of mice 
with pertussis toxin (PTX), which inhibits all 
Gi signaling, leads to a selective loss of B cells 
from the MZ (Guinamard et al., 2000). Posi-
tioning of MZ B cells is promoted by sphingo-
sine-1-phosphate (S1P), which signals primarily 
through S1P receptor 1 (S1P1) and, to a lesser 
extent, through S1P receptor 3 (S1P3) to over-
come the follicular attracting activity of the 
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Specialized B cells residing in the splenic marginal zone (MZ) continuously survey the blood for 
antigens and are important for immunity to systemic infections. However, the cues that uniquely 
attract cells to the MZ have not been defined. Previous work demonstrated that mice deficient in 
cannabinoid receptor 2 (CB2) have decreased numbers of MZ B cells but it has been unclear 
whether CB2 regulates MZ B cell development or positioning. We show that MZ B cells are 
highly responsive to the CB2 ligand 2-arachidonylglycerol (2-AG) and that CB2 antagonism 
rapidly displaces small numbers of MZ B cells to the blood. Antagonism for longer durations 
depletes MZ B cells from the spleen. In mice deficient in sphingosine-1-phosphate receptor 
function, CB2 antagonism causes MZ B cell displacement into follicles. Moreover, CB2 over-
expression is sufficient to position B cells to the splenic MZ. These findings establish a role for 
CB2 in guiding B cells to the MZ and in preventing their loss to the blood. As a consequence of 
their MZ B cell deficiency, CB2-deficient mice have reduced numbers of CD1d-high B cells.  
We show that CB2 deficiency results in diminished humoral responses to a CD1d-restricted 
systemic antigen.
© 2011 Muppidi et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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raising the question of whether CB2 could also promote 
cell positioning in the spleen, a possibility which we ex-
plored here.
RESULTS AND DISCUSSION
CB2 can act as a positional cue for MZ B cells
Previous work demonstrated that PTX treatment of mice 
caused a rapid loss of MZ B cells from the spleen (Guinamard 
et al., 2000). To determine whether this outcome reflected 
a B cell–intrinsic requirement of Gi signaling for normal 
accumulation of MZ B cells, we crossed CD21-Cre+ mice 
(Kraus et al., 2004) to mice in which the ADP-ribosylating 
subunit of PTX has been introduced into the ROSA26 locus 
but whose expression was prevented by a premature stop 
codon flanked by loxP sites (ROSA26PTX mice; Regard et al., 
2007). We found there was a striking loss of MZ B cells 
in CD21-Cre+ ROSA26PTX mice compared with WT con-
trols (Fig. 1 A), whereas follicular B cell numbers were preserved 
chemokine CXCL13 signaling through its receptor CXCR5 
on MZ B cells (Cinamon et al., 2004, 2008). However, in the 
absence of signaling through both S1P1 and CXCR5, MZ 
B cells remain positioned within the MZ, in contrast to the 
loss of MZ B cells after PTX treatment, suggesting that there 
are additional inputs through receptors coupled to Gi that 
mediate positioning of MZ B cells.
The Gi-coupled cannabinoid receptor 2 (CB2) is ex-
pressed in several immune cell types including B cells (Galiègue 
et al., 1995). The endocannabinoid 2-arachidonylglycerol 
(2-AG) is present within the spleen (Sugiura et al., 2006) and 
can act as a chemoattractant for mature B cells in vitro 
(Tanikawa et al., 2007). Mice deficient for CB2 have fewer 
MZ B cells than WT mice (Ziring et al., 2006). However, it is 
currently unclear whether CB2 deficiency results in defects 
in MZ B cell development, retention, positioning, or func-
tion. Recently it was shown that CB2 promotes retention of 
immature B cells within BM sinusoids (Pereira et al., 2009a), 
Figure 1. CB2 acts as a positional cue for MZ  
B cells. (A) Flow cytometry of splenic B cells from 
irradiated mice reconstituted with BM from either WT 
or CD21-Cre+ ROSA26PTX mice. Dot plots are gated on 
CD19+ cells. Numbers indicate percentage of B cells 
in the outlined gates. Data are representative of more 
than five mice of each type. (B) Quantitative PCR 
analysis of Cnr2 transcripts in sorted follicular B cells 
(FoB) and MZ B cells (MZB), presented relative to 
Hprt1 expression. One of at least four independent 
experiments is shown. (C) Chemotactic responses of 
MZ B cells (CD21hiCD23loB220+) and follicular B cells 
(CD21intCD23hiB220+) toward 2-AG, 100 ng/ml 
CXCL12, or 1 µg/ml CXCL13. One of six independent 
experiments is shown. (D) Chemotactic responses of 
MZ B cells toward 10 µM 2-AG, 100 ng/ml CXCL12,  
or 1 µg/ml CXCL13 in the absence or presence of the 
indicated concentrations of the CB2 antagonist 
SR144528. One of three independent experiments is 
shown. Error bars in C and D represent SEM. (E) MZ  
B cells per spleen (gated as in A) in CB2 heterozygous 
(Cnr2+/) or CB2-deficient animals (Cnr2/). Data 
shown are pooled data from three independent ex-
periments with two to four mice per group. (F) Per-
centage of MZ B cells labeled 5 min after i.v. injection 
of anti–CD19-PE in mice treated with SR144528 or 
vehicle for 3 h (left) or Cnr2+/ or Cnr2/ mice 
(right). Data shown are pooled from three or more 
independent experiments with greater than two mice 
per group. (G) Flow cytometry of the binding of 
CD19-PE antibody 5 min after i.v. injection by splenic 
MZ B cells in mice treated with vehicle or FTY720 for 1.5 h, followed by vehicle or SR144528 for a further 3 h. Numbers indicate fraction of cells in the 
indicated gate, shown as mean ± SD (n = 3 mice). P < 0.01. Histograms are gated on B220+CD21hiCD23lo MZ B cells. Data shown are one of two indepen-
dent experiments with at least two mice per group. (H) Percentage of MZ B cells labeled 5 min after i.v. injection of anti–CD19-PE in WT or CB2-deficient 
chimeric mice treated with FTY720 for 4.5 h. Shown are pooled data from two independent experiments representative of three with at least four mice 
per group. (I) Percentage of MZ B cells labeled 5 min after i.v. injection of anti–CD19-PE in Cxcl13/ mice treated as in G. (J and K) Flow cytometry (J) or 
percentage of MZ B cells labeled with CD19-PE antibody 5 min after injection (K) in Cxcl13/ mice reconstituted with S1P3-deficient (S1pr3/) BM 
treated as in F and G. Data in K are pooled data from two independent experiments with one to two mice per group. (L) Immunohistochemistry of spleen 
sections from mice in J stained for CD1d (blue) and MAdCAM1 (brown). Data are representative of at least three mice of each type. Bar, 100 µm. In all dot 
plots, dots indicate individual mice and lines indicate means.
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relocalization of most cells into follicles (Cinamon et al., 
2004). Importantly, this fraction of labeled MZ B cells was 
further reduced in mice treated with SR144528 in addition 
to FTY720 (Fig. 1 G), indicating a further displacement of 
cells from the MZ into follicles. FTY720 treatment of CB2-
deficient mice also caused a larger reduction in the fraction of 
labeled MZ B cells than occurred after treatment of WT mice 
(Fig. 1 H). In mice deficient for CXCL13, nearly all MZ 
B cells are positioned in the MZ as assessed by both in vivo 
labeling and immunohistochemistry (Fig. 1 I; Cinamon et al., 
2004). After treatment with FTY720, the fraction of MZ 
B cells labeled in vivo in CXCL13-deficient mice was reduced 
to 70% (Fig. 1 I). The fraction of MZ B cells labeled in vivo 
was further reduced when CXCL13-deficient mice were 
treated with SR144528 in addition to FTY720 (Fig. 1 I). This 
small reduction in cell positioning in the MZ was not easily 
visualized by immunohistochemistry (unpublished data). In 
addition to S1P1, S1P3 (encoded by S1pr3) contributes to 
positioning MZ B cells within the MZ (Cinamon et al., 
2004). S1P3 is not down-regulated after exposure to the ac-
tive form of FTY720 (Sensken et al., 2008). To remove this 
additional Gi-coupled receptor, we generated radiation chi-
meras using S1P3-deficient BM to reconstitute CXCL13- 
deficient hosts. When these chimeras were treated with 
FTY720 to functionally antagonize S1P1, 50–60% of the cells 
remained blood exposed (Fig. 1, J–L, middle). Administration of 
CB2 antagonist in addition to FTY720 now resulted in a large 
change in the distribution of MZ B cells, leaving only 25% of 
the cells in the blood-exposed MZ (Fig. 1, J and K). By immuno-
histochemical analysis of spleen sections, using CD1d to detect 
MZ B cells and MAdCAM1 to detect marginal sinus lining 
cells that delineate the boundary of MZ and white pulp, we 
found a redistribution of MZ B cells into the white pulp in 
mice treated with CB2 antagonist (Fig. 1 L). Accumulation of 
these multiple receptor–deficient MZ B cells within the white 
pulp may be mediated by CCR7 and/or EBI2 signaling 
(not depicted), confirming that there is a critical intrinsic 
requirement for Gi signaling to establish or maintain the 
MZ B cell population.
Transcripts encoding the Gi-coupled receptor CB2 are 
abundant in both MZ and follicular B cells (Fig. 1 B). In 
migration assays, MZ B cells showed significantly greater 
chemotactic responses toward 2-AG than follicular B cells 
(Fig. 1 C). 2-AG–induced migration was blocked by the highly 
selective CB2 antagonist SR144528 (Rinaldi-Carmona et al., 
1998), whereas migration to CXCL13 and CXCL12 was 
not affected by SR144528 (Fig. 1 D), establishing that the 
compound was not having nonspecific effects on MZ B cell 
migration. In agreement with previously published data 
(Ziring et al., 2006), mice deficient in CB2 (encoded by Cnr2) 
had decreased MZ B cells compared with heterozygous 
littermate controls (Fig. 1 E).
To assess MZ B cell positioning in vivo in mice deficient 
for CB2 or mice treated for 3 h with the CB2 antagonist 
SR144528, we used a previously described antibody pulse- 
labeling technique in which PE-labeled CD19 antibody is 
administered i.v. for 5 min to preferentially label B cells within 
vascular spaces such as the MZ (Cinamon et al., 2008; Pereira 
et al., 2009a). In WT C57BL/6 mice, 50–60% of MZ B cells 
are located in the blood-exposed MZ compartment at any 
given moment and the remainder are sheltered within the 
adjacent follicles (Cinamon et al., 2008). We found that the 
proportion of MZ B cells localized within the MZ compart-
ment was not altered in WT mice treated with SR144528 or 
in CB2-deficient mice as determined by in vivo labeling as 
well as immunohistochemistry (Fig. 1 F and not depicted). We 
then asked whether the contribution of CB2 to MZ B cell posi-
tioning might be revealed by removing other Gi inputs 
known to affect positioning of these cells. In mice given 
FTY720 to functionally antagonize S1P1 signaling (Brinkmann 
et al., 2010), only a small percentage of MZ B cells were 
CD19-PE antibody labeled in vivo (Fig. 1 G) as a result of 
Figure 2. CB2 retains MZ B cells within 
the spleen. (A) Flow cytometry of blood from 
mice treated with vehicle or the CB2 antago-
nist SR144528 for 3 h. Dot plots are gated on 
B220+ cells. Numbers are means (±SD) of 
percentage of B cells in this gate for the indi-
cated number of mice. P < 0.001. Data are 
representative of at least four independent 
experiments with at least four mice per group. 
(B) MZ B (MZB) cell and follicular B (FoB) cell 
counts from blood and spleen from mice 
treated as in A. Data are pooled from three 
independent experiments with four to six 
mice per group. (C) MZ B cells as percent of 
B220+ cells in blood from mice treated with 
vehicle or FTY720 for 1.5 h followed by vehicle 
or SR144528 for 3 h. Data are pooled from 
three experiments with two to five mice per 
group. (D) MZB and FoB cell counts per spleen from mice treated twice daily with SR144528 for 8 d. Data are pooled from four experiments with two to 
five mice per group. (E) BrdU-positive cells as percent of MZ B cells from Cnr2+/+, Cnr2+/, or Cnr2/ mice treated with BrdU in drinking water for 8 d. 
Data are pooled from three experiments with two to four mice per group. In all dot plots, dots indicate individual mice and lines indicate means.
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cell loss over long periods of time. We found that after 16 
treatments with SR144528 over an 8-d period, MZ B cells 
were decreased by approximately one third, whereas there 
was no statistically significant change in splenic follicular 
B cell numbers (Fig. 2 D).
It was possible that CB2 deficiency decreased MZ B cell 
numbers by decreasing the generation of new MZ B cells. 
CB2-deficient, heterozygous, or WT mice were treated with 
BrdU containing drinking water for 8 d and then assessed for 
BrdU incorporation by flow cytometry. There was a similar 
amount of BrdU incorporation by MZ B cells in CB2 defi-
cient mice compared with either heterozygote or WT con-
trols (Fig. 2 E), suggesting that there are not major differences 
in MZ B cell turnover in CB2-deficient and control mice but 
not excluding minor differences.
Collectively, these findings suggest that an important 
function of CB2 in MZ B cells is to promote their retention 
in the spleen. We postulate that CB2 antagonism for longer 
periods of time, or CB2 deficiency, reduces the number of 
MZ B cells through ongoing loss of normally non-recirculatory 
MZ B cells into the blood. However, we do not exclude the 
possibility that CB2 also functions to promote MZ B cell de-
velopment or survival.
CB2 overexpression is sufficient to position B cells  
to the MZ
To better understand the role of CB2 in MZ B cell position-
ing, we tested whether increased CB2 expression was suffi-
cient to alter B cell localization. Activated B cells were 
(Ohl et al., 2003; Pereira et al., 2009b). Both CCR7 and EBI2 
are expressed in MZ B cells at similar levels to follicular B cells, 
and MZ B cells migrate toward the CCR7 ligand CCL21 and 
the EBI2 ligand 7,25-dihydroxycholesterol (unpublished 
data). These findings demonstrate that CB2 acts as positional 
cue for MZ B cells and that its positional function is most 
apparent in the absence of S1P1, S1P3, and CXCR5 signaling.
CB2 retains MZ B cells in the spleen
Although there was no appreciable difference in positioning 
of MZ B cells after treatment with CB2 antagonist in WT 
mice, we did notice a small increase in MZ B cells within the 
blood 3 h after the treatment (Fig. 2, A and B). There was no 
increase in follicular B cells in the blood nor was there a mea-
surable decrease in MZ B cells in the spleen at this time point 
(Fig. 2 B). Integrins are involved in retaining MZ B cells 
within the spleen and MZ B cells exhibit high in vitro adhe-
sive activity to VCAM1 and ICAM1 (Lu and Cyster, 2002). 
However, MZ B cell adhesion to either VCAM1 or ICAM1 
in a static in vitro adhesion assay was not significantly affected 
by addition of 2-AG or CB2 antagonist (unpublished data). 
We hypothesized that the release of MZ B cells to the blood 
after CB2 antagonism was dependent on intact S1P1 signal-
ing. We found that when mice were pretreated with FTY720 
to functionally antagonize S1P1, CB2 antagonism was less 
efficient in releasing MZ B cells into the blood (Fig. 2 C).
Treatment with CB2 antagonist did not alter splenic 
MZ B cell numbers after 3 h (Fig. 2 B, right). However, it seemed 
possible that there might be a cumulative effect of continued 
Figure 3. CB2 overexpression is sufficient 
to position B cells to the MZ. (A–C) CD45.1+  
B cells retrovirally transduced with vectors en-
coding either control surface receptor (truncated 
nerve growth factor receptor) or CB2, as well as 
the reporter hCD4, were transferred into CD45.2+ 
recipient mice. Mice were analyzed 16 h later.  
(A) Immunohistochemical staining of splenic 
cryosections shows localization of hCD4+ trans-
duced cells (brown) and endogenous B cells 
(blue). (B) Flow cytometry of hCD4 expression in 
transferred retrovirally transduced B cells.  
(C) Flow cytometry of the binding of CD19-PE 
antibody 5 min after i.v. injection by donor 
CD45.1+ B cells in recipient mice. Transduced  
B cells (hCD4+) are shown in blue, co-transferred 
nontransduced B cells (hCD4) in gray. (D) Co-
localization of CB2-transduced cells (hCD4; 
brown) with B cell and macrophage markers 
(B220, CD169, and SIGNR1; blue) in adjacent 
sections. Data in A–D are representative of one 
of three independent experiments. (E and F) CB2-
transduced CD45.1+ B cells were transferred into 
CD169DTR or littermate control mice that had 
been treated with diphtheria toxin. (E) Immuno-
histochemical staining of splenic cryosections.  
(F) Flow cytometry of the binding of anti–CD19-
PE 5 min after i.v. injection by transferred CD45.1+ B220+ B cells. (G and H) CB2-transduced CD45.1+ B cells were transferred into mice treated 2.5 wk earlier with 
liposomal clodronate or PBS. Analysis was as in E and F. Data in (E–H) are representative of two independent experiments of each type. Bars, 100 µm.
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were similarly abundant in CB2-deficient mice compared 
with WT (unpublished data).
CB2 is required for optimal CD1d-restricted  
humoral responses
It has been difficult to establish the contribution of MZ B cells 
to T cell–independent humoral responses to model antigens. 
A previous study showed that mice lacking MZ B cells as 
a result of impaired Notch signaling had essentially normal 
transduced with a retrovirus containing a CB2 insert and a 
human CD4 (hCD4) reporter, or with a control retrovirus 
lacking the CB2 insert, and transferred into WT recipient 
mice, and positioning of transduced B cells was assessed after 
16 h. Strikingly, CB2 overexpression was sufficient to position 
B cells to the MZ (Fig. 3 A). This contrasts with the effect of 
S1P1 overexpression, where cells distribute through the red 
pulp without any preference for the MZ (Lo et al., 2005). The 
stronger and more diffuse staining of the CB2-transduced 
cells likely reflects the higher reporter expression on these 
cells compared with vector transduced cells (Fig. 3 B). In vivo 
labeling with anti–CD19-PE confirmed that many CB2-
transduced B cells were positioned in blood-exposed spaces 
in the spleen, whereas control transduced B cells were not 
(Fig. 3 C). The distribution of CB2-overexpressing B cells in 
the MZ suggests that CB2 ligand is concentrated in this area. 
Macrophage cell lines have been reported to produce the endo-
cannabinoid 2-AG in vitro (Sugiura et al., 2006) and macro-
phages have been implicated in retaining MZ B cells in the 
MZ (Karlsson et al., 2003). There are two major macrophage 
populations in the MZ. Marginal metallophilic macrophages 
can be identified by their high expression of CD169 and re-
side at the interface of the MZ and follicle (Mebius and Kraal, 
2005). MZ macrophages, identified by expression of the C-type 
lectin SIGNR1, reside within the MZ (Mebius and Kraal, 
2005). CB2-overexpressing B cells colocalized more closely 
with marginal metallophilic macrophages than MZ macrophages 
(Fig. 3 D). To assess the contribution of marginal metallophilic 
macrophages to positioning of CB2-overexpressing B cells, 
mice expressing diphtheria toxin receptor (DTR) from the 
CD169 locus (CD169DTR mice; Miyake et al., 2007) or litter-
mate controls were treated with diphtheria toxin to deplete 
CD169+ cells and then given CB2-transduced B cells. The 
CB2-overexpressing cells could position to the MZ and 
access vascular spaces as assessed by in vivo labeling despite an 
absence of CD169+ cells (Fig. 3, E and F). To test the possibil-
ity that MZ macrophages contributed to ligand production, 
mice were treated with liposomes containing clodronate. MZ 
macrophages remain absent for several weeks after treatment 
with liposomal clodronate (van Rooijen et al., 1989). Such 
treatments were found to cause an acute disruption in white 
pulp organization that lasted for several days (unpublished 
data). To allow time for repopulation of B cells in the follicles, 
we transferred CB2-transduced B cells into mice between 2 
and 3 wk after liposomal clodronate administration. Despite 
an absence of SIGNR1 staining, CB2-transduced B cells 
were able to position in the MZ of clodronate-treated animals 
(Fig. 3, G and H). These results suggest that CB2 ligand is 
concentrated within the splenic MZ and that neither mar-
ginal metallophilic macrophages nor MZ macrophages con-
tribute significantly to the distribution of CB2 ligand in vivo. 
Given this and the evidence of CB2 expression by some my-
eloid cell types (Munro et al., 1993; Sugiura et al., 2004), we 
asked whether CB2 deficiency affected splenic macrophage 
populations. Combined CD169 and SIGNR1 staining of 
spleen sections showed that both macrophage populations 
Figure 4. Diminished early antibody production to CD1d-restricted 
antigen in CB2-deficient mice. (A) Flow cytometric analysis of CD1d 
expression on CB2-deficient and WT splenic B cells from a mixed chimera. 
Histogram is gated on B220+ cells. Background CD1d staining of  
non–B cells is shown in gray. A representative of five mice is shown.  
(B) NP-specific IgM assessed by ELISA in serum from CB2-deficient or 
heterozygous littermates that had been immunized i.v. with NP-GalCer. 
Serum was collected before (preimm) and 4 d after immunization. Data 
are shown in relative units (RU) and are pooled from three independent  
experiments with four to seven mice per group. (C–E) ELISA analysis of 
serum from 1:1 mixed CB2-deficient or WT IgHb and WT IgHa BM chimeric 
mice. (C) Mixed chimeras were immunized i.v. with NP-GalCer.  
NP-specific IgMb (left) and IgMa (right) in serum from the indicated time 
points. (D) Mixed chimeras were immunized i.p. with OVA in alum. OVA-
specific IgG1b (left) and IgG1a (right) in serum from the indicated time  
points. (E) Contribution of CB2-deficient or WT (IgHb) BM compared with 
WT BM (IgHa) in MZ B cells (left) or follicular B (FoB) cells (right) of mixed 
chimeras. Data in C–E are representative of at least two independent  
experiments with four or more mice per group. In all dot plots, dots  
indicate individual mice and lines indicate means.
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tor is likely to be the high integrin adhesive function of MZ 
B cells and the abundant integrin ligand expression in the MZ 
(Lu and Cyster, 2002). We suggest that an additional factor is 
CB2-mediated attraction to locally produced ligand. MZ B cells 
respond more strongly to the endocannabinoid 2-AG than 
follicular B cells, and previous work has shown that small 
in vitro differences in chemotactic responsiveness can be associ-
ated with large in vivo effects on cell position (Reif et al., 
2002; Bromley et al., 2005; Hardtke et al., 2005). In CB2-
deficient animals, ongoing loss to the blood may account, at 
least partially, for the decreased number of MZ B cells. We do 
not exclude the possibility that CB2 also contributes to promot-
ing the development or survival of MZ B cells. We propose that 
stromal cells within the MZ, such as the marginal sinus lining 
cells, are responsible for CB2 ligand generation. The CD1d-
restricted humoral response to GalCer-containing antigens 
depends on interactions with iNKT cells (Barral et al., 2008; 
Leadbetter et al., 2008). Although it has so far been prob-
lematic to selectively detect iNKT cell distribution in situ 
within nontransgenic mouse tissues, by in vivo CD45 anti-
body labeling and flow cytometry we found that a higher 
fraction of CD1d-tetramer binding iNKT cells than con-
ventional CD3 T cells were in blood-exposed regions of the 
spleen (54 ± 1 vs. 20 ± 2%; n = 10; P < 0.001), consistent 
with the presence of some iNKT cells in the MZ. Although 
we cannot exclude the possibility that CB2 deficiency affects 
CD1d-restricted B cell responses in additional ways, we feel 
that the present data support the conclusion that MZ B cells 
make a prominent contribution to the early antibody response 
against CD1d-restricted systemic antigens.
MATERIALS AND METHODS
Mice and BM chimeras. Adult C57BL/6 (CD45.2+) and Ly5.2 (CD45.1+) 
mice 7–10 wk of age were from the National Cancer Institute. Cnr2/ mice 
(005786; The Jackson Laboratory; MGI 3604531) were backcrossed to 
C57BL/6 mice for 7–10 generations. ROSA26PTX mice were on a mixed 
B6-129 background (Regard et al., 2007). CD169DTR mice (Miyake et al., 
2007; MGI 3720841) were backcrossed to C57BL/6 for at least seven gener-
ations. CXCL13/ mice (MGI 1888499) and S1pr3/ (MGI 1339365; 
provided by R. Proia, National Institutes of Health, Bethesda, MD) were on 
a B6 background. BM chimeras were made as previously described (Pereira 
et al., 2009a) and analyzed at least 7 wk after reconstitution. Mice were 
housed in a specific pathogen-free environment in the Laboratory Animal 
Research Center at the University of California, San Francisco (UCSF), and 
all animal procedures were approved by the Institutional Animal Care and 
Use Committee.
Treatments. For short-term CB2 blocking experiments, mice were injected 
once in the tail vein with 200 µl of 0.1% ethanol in PBS (carrier) or with 10 µg 
CB2 antagonist SR144528 (obtained from the National Institute of Mental 
Health’s Chemical Synthesis and Drug Supply Program), dissolved in 0.1% 
ethanol in PBS. For long-term blocking of CB2 function, mice were injected 
i.p. twice a day with either 10 µg SR144528 or carrier for 8 d. For FTY720 
pretreatment, mice were injected intraperitoneally at 1 mg FTY720 per kg 
body weight or an equivalent volume of saline 1.5 h before administration 
of CB2 antagonist. Liposomal clodronate or PBS was obtained from 
N. van Rooijen (clodronateliposomes.org; Free University Medical Center, 
Amsterdam, Netherlands) and was administered at a dose of 10 µl/g by i.v. 
injection by tail vein. Diphtheria toxin (EMD Biosciences) was administered 
at a dose of 30 ng/g intraperitoneally 3 and 1 d before transfer of cells. For BrdU 
humoral responses to haptenated T cell–independent antigens 
such as lipopolysaccharide or Ficoll (Tanigaki et al., 2002). 
MZ B cells express high levels of the MHC class I–like mole-
cule CD1d that can present lipid antigens to iNKT cells 
(Pillai and Cariappa, 2009). CB2-deficient mice have a lower 
frequency of CD1dhi B cells in the spleen than WT mice, 
consistent with the reduced number of MZ B cells (Fig. 4 A). 
MZ B cells activate T cells more rapidly and efficiently than 
follicular B cells (Attanavanich and Kearney, 2004) and re-
cent in vitro experiments have indicated that lipid-loaded 
MZ B cells promote greater iNKT cell activation than fol-
licular B cells (Barral et al., 2008; Leadbetter et al., 2008). To 
determine if CB2 deficiency impaired the ability of mice to 
mount CD1d-restricted humoral responses, we i.v. immunized 
CB2-deficient or littermate control mice with the haptenated 
lipid antigen 4-hydroxy-3-nitrophenyl (NP)-Galactosyl-
Ceramide (NP-GalCer; Leadbetter et al., 2008). Because 
the MZ B cell response to T cell–independent antigens peaks 
at day 3–4, earlier than the follicular response (Martin and 
Kearney, 2001), we examined serum antibody levels at this 
early phase of the response. CB2-deficient mice showed 
an impaired antigen-specific IgM antibody production to 
NP-GalCer 4 d after immunization (Fig. 4 B). To determine 
whether this diminished response reflected a B cell–intrinsic 
defect, we generated mixed chimeras using CB2-deficient or 
CB2-WT IgHb donors and WT IgHa donors. Serum collected 
from CB2-deficient mixed chimeras 4 d after immunization 
showed impaired IgMb responses compared with CB2-WT 
mixed chimeras (Fig. 4 C, left). In contrast, IgMa, produced 
by WT B cells in CB2-deficient mixed chimeras, trended to-
ward increased responses compared with WT mixed chimeras 
(Fig. 4 C, right). We next assessed humoral responses of mixed 
chimeras immunized with the conventional T cell–dependent 
antigen ovalbumin in the adjuvant alum. We found no differ-
ence in IgG1b or IgG1a production between CB2-deficient 
and CB2-WT mixed BM chimeras (Fig. 4 D). Analysis of 
the B cell contribution to the MZ compartment revealed a 
decreased contribution of CB2-deficient compared with WT 
B cells, whereas follicular B cells of the two genotypes were 
equally represented (Fig. 4 E). The decrease in MZ B cells de-
rived from CB2-deficient BM was proportional to the decrease 
in NP-specific IgMb production in these animals. Conversely, 
the trend toward increased NP-specific IgMa production 
in CB2-deficient mixed chimeras was proportional to the 
increase in MZ B cells derived from WT IgHa BM. These 
results suggest that decreases in the size of the MZ B cell 
compartment as a result of CB2 deficiency lead to decreased 
CD1d-restricted humoral responses.
In summary, we show that CB2 provides a Gi-coupled 
input that promotes B cell tropism for the splenic MZ. Pre-
vious work has led to a model where MZ B cells shuttle 
between the MZ and follicle in cycles promoted by alternat-
ing responses to S1P and CXCL13 (Cinamon et al., 2008). 
However, S1P is unlikely to be more abundant in the MZ 
than in the blood or red pulp, raising the question of what 
factors prevent MZ B cell egress from the spleen. One fac-
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